Analysis of Strong Performance of Jindike (688670): Driven by Flu Season Demand and Production Resumption Benefits

This analysis is based on tushare_strong_pool data, and Jindike (688670) has recently entered the strong stock pool.

1. Flu Season Demand Rise
   : It is the traditional flu season (November-January of the following year), and the flu prevalence period has advanced in many regions, strengthening market expectations for flu vaccine demand [0].
2. Production Resumption Benefit
   : The company’s workshops have resumed normal production, and Huaxin Securities released a research report with a buy rating [0].
3. Industry Policy Support
   : The 2025 National Medical Insurance Negotiation will increase support for innovative drugs, and the new version of the medical insurance catalog is expected to accelerate the sales volume of drugs [0].

• Stock Price Trend
  : On November 14, 2025, the stock price closed at 28.03 yuan, with a single-day increase of 19.99%, a turnover of 269.6 million yuan, and an amplitude of 24.06% [0].
• Dragon-Tiger List Situation
  : From November 11 to 14, it appeared on the dragon-tiger list multiple times. On November 11, it was disclosed because the cumulative deviation value of the increase over three consecutive trading days reached 30% [0].

The biopharmaceutical industry is expected to maintain growth from 2024 to 2030 [3]. The pharmaceutical sector’s third-quarter revenue increased by 1.36% year-on-year, and net profit attributable to parent companies rose by 3.13% year-on-year [0], improving the industry’s fundamentals.